Success of Cyclosporin and Tofacitinib Combination Therapy in a Patient With Severe Steroid-refractory Ulcerative Colitis
© 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
At present, the conventional therapies for acute severe ulcerative colitis (ASUC) mainly include corticosteroids, cyclosporin, and biological agents. However, the treatment of patients with severe steroid-refractory ulcerative colitis remains a serious challenge to clinicians. This study reports a case of steroid-refractory ASUC treated with cyclosporin combined with tofacitinib after treatment failure with infliximab.
| Errataetall: |
CommentIn: Inflamm Bowel Dis. 2022 Mar 30;28(4):e46. - PMID 35045169 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Inflammatory bowel diseases - 27(2021), 12 vom: 15. Nov., Seite e157-e158 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Qinglu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
83HN0GTJ6D |
|---|
| Anmerkungen: |
Date Completed 10.02.2022 Date Revised 22.05.2022 published: Print CommentIn: Inflamm Bowel Dis. 2022 Mar 30;28(4):e46. - PMID 35045169 Citation Status MEDLINE |
|---|
| doi: |
10.1093/ibd/izab181 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329418637 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329418637 | ||
| 003 | DE-627 | ||
| 005 | 20231225205058.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ibd/izab181 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1098.xml |
| 035 | |a (DE-627)NLM329418637 | ||
| 035 | |a (NLM)34398196 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Qinglu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Success of Cyclosporin and Tofacitinib Combination Therapy in a Patient With Severe Steroid-refractory Ulcerative Colitis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.02.2022 | ||
| 500 | |a Date Revised 22.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Inflamm Bowel Dis. 2022 Mar 30;28(4):e46. - PMID 35045169 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a At present, the conventional therapies for acute severe ulcerative colitis (ASUC) mainly include corticosteroids, cyclosporin, and biological agents. However, the treatment of patients with severe steroid-refractory ulcerative colitis remains a serious challenge to clinicians. This study reports a case of steroid-refractory ASUC treated with cyclosporin combined with tofacitinib after treatment failure with infliximab | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Piperidines |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a Steroids |2 NLM | |
| 650 | 7 | |a Cyclosporine |2 NLM | |
| 650 | 7 | |a 83HN0GTJ6D |2 NLM | |
| 650 | 7 | |a tofacitinib |2 NLM | |
| 650 | 7 | |a 87LA6FU830 |2 NLM | |
| 700 | 1 | |a Chen, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Lijin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Changqin |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Leilei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhanju |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Xiaomin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammatory bowel diseases |d 1995 |g 27(2021), 12 vom: 15. Nov., Seite e157-e158 |w (DE-627)NLM094498598 |x 1536-4844 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:12 |g day:15 |g month:11 |g pages:e157-e158 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ibd/izab181 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 12 |b 15 |c 11 |h e157-e158 | ||